Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 3 · 42.9%Moderate 1 · 14.3%High 0 · 0%

Oral magnesium pidolate vs placebo or no intervention

Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Moderate

Long‐term red cell transfusion vs usual care

SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD and abnormal TCD velocities

It is very uncertain whether long‐term RBC transfusion changes SCD‐related SAEs ‐ pain crisis compared with standard care (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 0.9 [0.44, 1.86]
1 study · 130 participants
Very low

Long‐term red cell transfusion vs usual care

SCD‐related SAEs ‐ pain crisis · SCD‐related SAEs and clinical stroke in people with SCD at risk of stroke and no previous long‐term RBC transfusions

Long‐term RBC transfusions may leads to lower SCD‐related SAEs ‐ pain crisis compared with standard care (low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 0.63 [0.42, 0.95]
2 studies · 326 participants
Low

Transfusions continued vs transfusions halted

SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD and normalised TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Very low

Hydroxyurea vs RBC transfusion

SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD who have not had a stroke (primary prevention)

It is very uncertain whether hydroxyurea changes SCD‐related SAEs ‐ pain crisis compared with RBC transfusions (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 5.08 [0.61, 42.23]
1 study · 121 participants
Very low

Hydroxyurea vs RBC transfusion

SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD who had a stroke (secondary prevention)

Hydroxyurea may leads to higher SCD‐related SAEs ‐ pain crisis compared with RBC transfusion (low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 3.15 [1.23, 8.11]
1 study · 133 participants
Low

Long‐term red cell transfusion vs usual care

SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD and normal TCD velocities

Long‐term RBC transfusion may leads to lower SCD‐related SAEs ‐ pain crisis compared with standard care (low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 0.56 [0.4, 0.78]
1 study · 196 participants
Low